Sustainability | September 17, 2024
Piramal Pharma's GHG Commitment Validated and Approved by SBTi
This validation aligns with Piramal Pharma's core purpose of 'Doing Well and Doing Good,'
This validation aligns with Piramal Pharma's core purpose of 'Doing Well and Doing Good,'
Tecentriq Hybreza provides patients and physicians with greater flexibility of treatment options while showing safety and efficacy consistent with intravenous
Both the products are Gadolinium based Magnetic Resonance Imaging (MRI) contrast agents and will be the first set of contrast agent products in Zydus’ injectable portfolio for the US market
The acquisition is based on an enterprise value of Rs. 1,660 crore
This aims to benefit approximately 4.5 crore families with six crore senior citizens with Rs. 5 lakh free health insurance cover on a family basis
The trial met its primary and secondary endpoints demonstrating that administration of a 3-dose regimen of GARDASIL 9
Jubilant HollisterStier is a subsidiary of Jubilant Pharma Holding
ALS patients experience neuroinflammation and rapid neurodegeneration
TROPION-Lung01, evaluating AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan versus chemotherapy, previously met the dual primary endpoint of progression-free survival in the overall trial population
The publication serves as a foundational tool for identifying gaps and addressing needs in various areas, including rural, urban, and tribal regions
Subscribe To Our Newsletter & Stay Updated
